Novo Holdings participates in divestment of VectivBio
Vevtivbio will soon be acquired by Ironwood, which will receive a phase III candidate against short bowel syndrome, a treatment that Zealand Pharma is also studying.
by albert rønning-andersson, translated by christian radich hoffman
With just two years in existence, Switzerland-based VectivBio will soon be handed off to US-based Ironwoods as the two companies’ executive boards have agreed to a trade of USD 17 per share, amounting to about USD 1.1bn in total, they write in a joint press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings invests in Swiss biotech company, enters board
For subscribers
Novo Holdings invests in biotech company for third time
For subscribers
